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Understanding genotype/phenotype relationships has become more complicated as increasing amounts of inter- and
intra-tissue genetic heterogeneity have been revealed through next-generation sequencing and evidence showing that
factors such as epigenetic modifications, non-coding RNAs and RNA editing can play an important role in determining
phenotype. Such findings have challenged a number of classic genetic assumptions including (i) analysis of genomic
sequence obtained from blood is an accurate reflection of the genotype responsible for phenotype expression in an
individual; (ii) that significant genetic alterations will be found only in diseased individuals, in germline tissues in
inherited diseases, or in specific diseased tissues in somatic diseases such as cancer; and (iii) that mutation rates in
putative disease-associated genes solely determine disease phenotypes. With the breakdown of our traditional
understanding of genotype to phenotype relationships, it is becoming increasingly apparent that new analytical
tools will be required to determine the relationship between genotype and phenotypic expression. To this end, we are
proposing that next-generation genetic database (NGDB) platforms be created that include new bioinformatics tools
based on algorithms that can evaluate genetic heterogeneity, as well as powerful systems biology analysis tools to
actively process and evaluate the vast amounts of both genomic and genomic-modifying information required to
reveal the true relationships between genotype and phenotype.
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Next-generation genetic databasesIntroduction
The problem of understanding the relationships between
genotype and phenotype has become very much more
complicated with the explosion of genetic information
produced by next-generation sequencing (NGS). This
information has greatly complicated not only our ability
to understand complex traits, but also our understand-
ing of monogenic traits is no longer quite so straight
forward. Indeed, recent articles have suggested the need
to develop new approaches to come to grips with the* Correspondence: bruce.gottlieb@mcgill.ca
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unless otherwise stated.ever-expanding complexity of genotype/phenotype rela-
tionships, such as ‘systems genetics’ [1] and ‘particle
genetics’ [2].
However, perhaps the most confusing from a ‘traditional’
genetics standpoint has been the revelation of unexpected
amounts of genetic variation in normal individuals, e.g.,
through the 1000 Genomes Project Consortium [3,4]
(www.1000genomes.org), and The Cancer Genome Atlas
(www.cancergenome.nih.gov) projects. Further, multiple
sequence comparisons both between and within an indi-
vidual's tissues have revealed extensive inter- and intra-
tissue genetic heterogeneity [5-7]. These discoveries have
raised some fundamental questions about our most basic
genetics assumptions, among which are the following: (i)
Can genetic studies still rely on a unique DNA or RNA se-
quence derived from blood or diseased tissue to determinel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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genome reference sequence really exist, or at least can the
reference sequence adopted by the NCBI (RefSeqGen)
be practically useful in determining genotype/pheno-
type relationships?; and (iii) Does genetic heterogeneity
in normal and diseased tissues imply that in certain
tissues an individual's genome will naturally undergo
somatic changes from conception to death as sug-
gested in Figure 1. In particular, newly revealed genetic
heterogeneity data could help explain the long observed,
but poorly understood concepts of variable expressivity
and reduced penetrance. Traditionally, their effects on
phenotypic differences have been considered to be rela-
tively insignificant, particularly so for variable expressivity.
To further complicate matters, phenotypic variations
have been found, where identical gene alterations have
been associated with (i) considerably different disease
phenotypes, e.g., in phenylalanine hydroxylase deficiency
(PAH) [8], or (ii) in a more extreme manner in the andro-
gen receptor (AR) gene, with both androgen insensitivity
syndrome (AIS) and prostate cancer [9].
In addition, there has also been an increase in the
discovery of significant phenotype-modifying events,
including epigenetic modifications, RNA editing, and
protein interactions that can clearly influence tran-
scriptional and non-transcriptional events involved in
determining the phenotype. Thus, these complex influ-
ences are also likely to render our traditional under-
standing of the relationship between genotype and
phenotype problematical. Further, a recent review of geno-
type/phenotype dissociation that discussed the possible
molecular basis of reduced penetrance in human inherited
disease, highlighted 12 molecular events that can influence
reduced penetrance [10], some of which are also likely
involved in situations of variable expressivity. In Figure 2,
we have suggested a model that incorporates some ofFigure 1 Factors that can affect an individual's genome from concept
occur during embryogenesis, and are then selected for later in life, to emphas
and the role of selection in determining phenotype.these processes, and how they might influence phenotype,
with special emphasis on the influence of intra-organismal
and intra-tissue genetic heterogeneity. Traditionally,
genetic databases have been the tools of choice in deter-
mining genotype/phenotype relationships; however, in
their present form, they are totally inadequate to deal
with these issues. Therefore, we are suggesting that it is
time to create next-generation genetic databases (NGDB)
that will be able to incorporate and analyze all of the fac-
tors that can contribute to the dissociation of genotype
from phenotype, including those that may contribute to
reduced penetrance and variable expressivity.
Factors that have been shown to influence phenotype
Somatic mutations that result in intra-organismal and
intra-tissue genetic heterogeneity
Until recently, it has been assumed that somatic muta-
tions are almost exclusively associated with cancers and
are uniform within an individual neoplasm. However,
different sets of somatic mutations have been found
within a single individual's cancer tissues, as in a recent
study of primary high-grade serous ovarian cancers that
revealed a considerable amount of intra-tumor genetic
heterogeneity [11].
Somatic sequence variants in normal tissues have also
been examined in relation to oncogenesis. One study
concluded that somatic sequence variants in normal cell
populations could be the earliest stage of oncogenesis
[12]. Evidence that altered mammary gland development
and predisposition to breast cancer is due to in utero
exposure to endocrine disruptors has suggested that
selection of cells with different phenotypic properties,
presumably as a result of very early somatic mutations,
may take place at the very earliest stages of breast tissue
development [13]. Thus, we may need to reconsider
whether accumulation of a critical number of oncogenicion to death. (1) We have postulated that somatic mutations may
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Figure 2 Phenotypic modifying factors. (1) Somatic mutations can include both single nucleotide variants and structural alterations such as
copy number variations that can then result in somatic and clonal mosaicism. (2) Cellular microenvironment selection pressure can work at the (i)
DNA level, i.e., due to somatic mutations or (A) DNA editing; (ii) RNA level, i.e., due to (B) RNA editing, (C) interacting RNAs, or (D) epigenetic
factors, etc.; or (iii) protein level, i.e., due to (E) protein-protein interactions. (3) Tissue microenvironment selection pressure can select a different
protein product. Crossing arrows reflect the fact that selection can go in either direction.
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is the reason that many cancers occur later in life.
Rather, it has been proposed that while the genetic ori-
gins of cancer may occur early in fetal development,
later selection pressure could explain the relationship
between aging and cancer [14]. Interestingly, a possible
mechanism to produce very early somatic mutations,
namely the temporarily deferring of the repair of DNA
lesions encountered during tissue replication, that has
been termed damage bypass, has been identified as
responsible for somatic hypermutation of the immu-
noglobin gene [15]. Regardless of which oncogenesis
hypothesis is eventually proven, the implications for
construction of NGDB for cancers is likely to be pro-
found, as NGDBs will need to consider incorporating
sequence data from much earlier stages in a tissue
development, particularly from tissues that have the
potential to become cancerous. Obviously, the ability to
do so at the moment is not practical, but it is possible to
envision that in the future, new micro-sampling tech-
niques, together with the continued dramatic decline inthe cost of NGS, will make such an approach much more
realistic.
In addition, as specific tissues are being sequenced
routinely, the number of other diseased tissues in which
somatic mutations have been found has increased con-
siderably [16]. More detailed studies have also reported
somatic mosaicism in a number of other conditions,
including the Proteus syndrome [17] and hemimegalen-
cephaly [18].
Further, a study of copy-number variants (CNVs) in
somatic human tissues revealed a significant number of
intra-individual genomic changes between tissues [19].
Other studies of chromosomal abnormalities, including
CNVs have revealed clonal mosaicism associated with
aging and cancer [14], as well as related it to a higher
risk of hematological cancer [20].
DNA editing
At the present state of our knowledge, this process is
still considered to be extremely rare and of little pheno-
typic significance [21].
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Recent, though controversial, evidence has suggested
that RNA editing occurs more frequently than previously
thought [22,23], although questions of how common it
actually is in normal tissues and the validity of the original
report have arisen [24-26]. However, there do appear to
be cases where modifications of disease phenotypes are
related to RNA editing [27,28].
Coregulators: non-coding RNAs
In recent years, non-coding RNAs (ncRNA) have been
found to play an important role in the phenotypic
expression of the transcribed genomic output. This family
of untranslated RNAs includes small nucleolar RNAs
(snoRNAs), which facilitate mRNA splicing, regulate
transcription factors, and repress gene expression [via
microRNAs (miRNAs)]. Small nuclear RNAs (snRNAs)
that alter cellular proliferation and apoptosis by means
of small interfering RNAs (siRNAs) have also been iden-
tified [29]. Long non-coding RNAs (lncRNAs) have also
been identified as possible regulators of gene trans-
cription and expression. Thus, the use of NGS to infer
transcript expression levels in general, specifically via
ncRNAs, is becoming increasingly common in molecu-
lar and clinical laboratories [30]. Therefore, it is not sur-
prising that ncRNAs have been implicated as being
responsible for a number of disease phenotypes [31].
Epigenetic factors
Epigenetics describes chromatin-based events that regu-
late DNA-templated processes and result in stable repro-
gramming of gene expression in response to transient
external stimuli. Primary epigenetic factors include modi-
fications to DNA and histones that are dynamically added
and removed by chromatin-modifying enzymes in a highly
regulated manner. Epigenetic mechanisms identified
include DNA methylation, phosphorylation, ubiquityla-
tion, sumoylation, RNA interference, and histone vari-
ance. Further, such epigenetic modifications play a
critical role in the regulation of DNA-based processes
such as transcription, DNA repair and replication,
which can affect phenotype expression. Thus, abnormal
expression patterns or genomic changes in chromatin
regulators can have profound effects on human disease
processes [32]. Indeed, epigenetics is considered a uni-
fying factor in the etiology of some complex traits [33].
Regulators and other types of interacting proteins
Over the past few years, phenotypic expression has also
found to be influenced by interacting proteins. Alter-
ations in the interacting surfaces of a specific molecule
[34] or the interacting proteins themselves can result in
faulty protein-protein interactions and contribute to a
disease phenotype [35].Selection pressure by cellular and tissue microenvironments
It has been proposed that tumor morphology and pheno-
type are driven by selective pressure from the tissue
microenvironment [36,37]. This hypothesis has been ex-
panded to include other genetically determined diseased
and non-diseased phenotypes [38]. The ability to perform
ultra-deep sequencing using next-generation sequencers
has revealed many more variants of a gene within tissues
and thus the possibility that evolution at the tissue level
contributes to disease phenotypes such as cancer [37,38].
Genotype/phenotype disconnects and possible
mechanisms
In light of all the potential phenotype-modifying factors
(Figure 2), which are generally not documented in trad-
itional genetic databases, it is easy to understand why
such databases, in their attempt to link a defined geno-
type with a specific phenotype, tend to avoid commenting
on genotype/phenotype disconnects, due to the lack of
information regarding the mechanisms that could produce
such effects. However, a recent review highlighted the
importance of understanding these disconnects, with over
650 references cited in proposing 12 molecular mecha-
nisms to explain reduced penetrance [10]. Similarly, a
number of possible mechanisms have been suggested to
explain variable expressivity, e.g., somatic mosaicism [39],
modifier genes [40], microRNA [41], epigenetic processes
[42], and allelic heterogeneity [43]. Originally, the concept
of reduced penetrance was based on studies of well-
known genetic conditions in which a family tree predicted
a disease phenotype, but this phenotype was not observed.
While in most cases, the likelihood of reduced penetrance
was small, it did serve a useful purpose in calculating the
possibility of an individual having a diseased phenotype.
The concept was further expanded when large-scale stud-
ies started to record the presence of mutations in specific
genes associated with multifactorial diseases, such as
cancer, a prime example being the breast cancer BRCA
genes. In these cases, predicting penetrance was consid-
ered important in assessing the risk of disease. What has
further complicated the issue, as we have noted, has been
recent data from the 1000 Genomes Project and other
large scale sequencing projects, which have reported that
normal individuals can contain tens of potentially severe
disease-associated alleles [10]. Thus, rather than talk about
reduced penetrance of a pathogenic variant in a cohort
that is known to express the disease phenotype, we now
have to consider why these pathogenic variants are non-
penetrant in a significant number of normal healthy
individuals.
Redefining the human genome reference sequence
Clearly, the arrival of relatively inexpensive whole gen-
ome sequencing, and the subsequent sequencing of large
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increasing presence of known disease-associated gene
variants within non-diseased individuals. This was ini-
tially shown when the first Korean genome sequence
was compared to other Asian genomes [44]. More
detailed studies found sequence variants in genes asso-
ciated with specific genetic disorders, in individuals
with normal phenotypes. Such examples were recently
discovered in a genomic analysis of 10 healthy individ-
uals, where each individual had what was said to be
‘healthy variance’ in 19 to 31 OMIM genes, as they did
not exhibit any of the signs, symptoms, or phenotypes
of the associated genetic disorders [45]. However, it
should be noted that not all sequence variants in
OMIM genes are always pathogenic, as has recently
been comprehensively reported [10]. Nevertheless, a
systematic survey of loss-of-function (LoF) variants
identified 26 known and 21 predicted severe disease-
causing variants in analysis of 2,951 putative LoF vari-
ants obtained from 185 human genomes [46]. What is
even more problematic is that our own work has identified
specific pathogenic sequence variants in the AR gene
in individuals with completely normal phenotypes,
i.e., exactly the same AR variants as found in diseased
individuals [9].
We believe this data calls into question the validity of
our present methods of defining the so-called normal
human genome. In particular, normal tissue genotype/
phenotype disconnects have clearly created questions
regarding the practicality of relying on a single unique
reference sequence as the definitive predictor of pheno-
type. The Human Genome Variation Society (HGVS)
nomenclature committee has studied this issue (www.
hgvs.org/mutnomen/refseq.html) and recommended
that the NCBI RefSeqGen be used and that the re-
ference sequence guidelines should follow the Locus
Reference Genomic (LRG) sequence format [47], which
suggests using a single-file record containing a unique
stable reference sequence. These recommendations were
appropriate at the start of NGS, when the extent of
variance in normal individuals, was relatively unknown.
Naturally, we understand that a definitive reference
sequence is important in defining exonic, intronic, and
other structural parameters of genes. However, the issue
of correlating phenotype with a specific sequence has
clearly become much more complex.
To deal with this issue, the increasing amount of
sequence variability in normal individuals has been
incorporated into the latest version of the NCBI
RefSeqGen (GRC37p13) (www.ncbi.nlm.nih.gov/pro-
jects/genome/assembly/grc/human), with the idea that
these variants could be used as a contextual filter to
determine the relationship between genotype and
phenotype. Furthermore, additional tools have been setup to deal with the issue of normal variance, such as
considering population-specific references where the
major alleles are included at every location, or generat-
ing a reference sequence where all the alleles have been
identified as part of the common ancestral lineage of
modern humans. However, we would argue that just
integrating normal human variance, however nuanced,
into an overall version of the RefSeqGen fails to deal
with the increasing problem of the association of the
same gene variant with both normal and diseased pheno-
types. Thus, relying solely on a DNA-based reference
sequence, however sophisticated, will make it very
difficult to distinguish between benign and disease-
causing gene alterations, at least in traditional genetic
databases, where the phenotypic classification of spe-
cific gene variants is based on having a unique refer-
ence sequence that is exclusively associated with a
normal phenotype.
Possible organization of next-generation genetic databases
As an overlying principle, NGDBs need to be organized
to take into consideration, particularly for multifactorial
diseases, the overall genetic context of any identified
mutation. However, context involves both intra-organismal
genetic heterogeneity as well as other phenotype-modifying
factors (Figure 2). These modifying factors also need to
be considered in the context of ‘pathway analysis’ [48].
In light of the many contextual factors that can affect
the genotype/phenotype expression, it seems reasonable
that future of locus-specific databases (LSDBs) should
be organized to take into account as much specific
phenotype information as possible, including genotype-
modifying factors, as opposed to most present LSDBs
that are primarily genotype centered.
The issue of how to deal with the increasing identifica-
tion of somatic mutations and intra-organismal genetic
heterogeneity also needs to be investigated. Tradition-
ally, somatic mutations have not been associated with
databases unless a cancer phenotype was involved. At
present, most disease-based databases associated with
common multifactorial diseases such as cancer, diabetes
and cardiovascular diseases often lack tissue and individ-
ual specific data. Indeed, only the COSMIC database
[49] lists a comprehensive spectrum of somatic muta-
tions associated with specific tissues and individual sam-
ples. Furthermore, currently, there is no description of
the germline susceptibility variants found in matching
control tissues, therefore making it difficult to draw
definitive conclusions as to the significance of many
somatic mutations. The situation will become even more
complex when inter- and intra-tumor genetic heterogen-
eity data is added. Clearly, traditional flat-file databases
will be unable to deal with such data and what are
needed are radically different database structures that
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it will be necessary to incorporate complex ‘system ana-
lysis tools’ that can analyze the intricate relationships be-
tween genotypic and phenotypic ontology [50]. Such
analysis tools will need to incorporate extremely power-
ful knowledge analysis engines, possibly similar in design
and organization to those developed by Google and
other search engine companies.
These knowledge engines, for ‘systems genetics ana-
lysis’, will require the creation of powerful new bioinfor-
matics tools and tremendously expanded database
resources, particularly for disease-based databases. In
particular, they will be required to analyze integrated
genetic and non-genetic variation across many datasets,
from different ethnic sub-groups or geographic popula-
tions, with the ultimate goal of integrating all genetic
and non-genetic databases for a particular condition, es-
pecially if an initial population-based analysis fails to
generate any significant insights into genotype/pheno-
type relationships. At the moment, such a task is clearly
far beyond our capabilities; however, initial studies using
mice have started to generate the bioinformatics tools
and database resources required to create such NGDBs
[51]. As NGDBs will include inter- and intra-tissue gen-
etic heterogeneity, one factor that needs to be consid-
ered is the importance of quantifying variants that result
in genetic heterogeneity, particularly if they are present
within individual genes, rather than simply recording
their presence. Indeed, we recently analyzed intra-tissue
genetic heterogeneity in the AR gene in both cancer and
non-cancer tissues taken from breast tumors and quanti-
fied AR variants in individual tissue samples using a new
NGS technique [52]. Another approach has been to con-
sider what has been termed ‘particle genetics’, where
every cell is considered to be genetically unique, using
probabilistic trait loci (PTL) to link genomic regions to
probabilities of cellular characteristics [2].
Taking all of these factors into consideration, we
would propose a NGDB model that integrates separate
databases for each of the potential genome-modifying
factors, together with a genotype database that incor-
porates genetic heterogeneity, with all of the individual
databases linked to an associated phenotype database,
and the data is then processed and analyzed through a
very sophisticated knowledge engine (Figure 3).
Summary of possible actions required to create NGDBs
The following are some of the most significant actions
that need to be undertaken in creating NGDBs:
1. Work in conjunction with the 1000 Genomes
Project consortium and the Human Variome Project
(HVP) to define the limits and significance of
normal genome variation.2. Incorporate individual inter- and intra-individual
genetic heterogeneity into NGDBs.
3. Establish guidelines as to the significance of the
number of reads needed to confirm a particular
variant. Note, that initial NGS sequencing depth
started at 4× to 10× coverage and rapidly rose to
where 30× to 50× coverage is considered normal.
However, recent studies show that increased
coverage is likely to result in increased detection of
variants [53,54], which in the case of tumor
diagnostics coverage has now reached up to 20,000
reads.
4. Determine how the different frequency of
occurrence of multiple gene variants within
individuals should be incorporated into NGDBs. It
should be noted that, at the moment, such
frequencies are generally not incorporated into
databases, particularly not into LSDBs. It would also
clearly help to integrate structural variant data such
as CNVs into LSDBs.
5. Incorporate expression data effectively into
phenotype data parameters in NGDBs. Note that
examples of tissue-specific variations in gene expres-
sion have now been reported [55]. In addition, data
from the Genotype-Tissue Expression project [56]
could be invaluable in determining relationships
between tissue gene expression and disease phenotype.
6. Finally, research the bioinformatics and data
parameters required to construct NGDBs that can
incorporate and analyze all of the above data. To be
truly effective, we believe that this effort should
involve experts in genetics, bioinformatics, and
systems biology-based search and knowledge engines,
as well as a worldwide effort to collect genetic
variation as for instance, proposed by the HVP.
Suggestions for future actions to be taken by the HVP
We believe that HVP is an organization that could play
a leading role in developing NGDBs first by creating a
special committee to look into future genetic database
designs to deal with some of the issues raised in this
article. Such a committee might include not only no-
menclature experts, but also experts in creating both the
algorithms required to design the databases, as well as
the search and analytical engines. Based on the recom-
mendations of this committee, the HVP could then set
up an Institute for Genetic Database Research, which in
addition to being responsible for NGDB design, could
create a working model of the infrastructure required to
run such databases on a worldwide scale. In particular, it
will be important to establish a universal design structure
so that all NGDBs will have a high degree of compatibil-
ity, and we believe that if such a design is coordinated































Figure 3 A model for next-generation genetic databases. (1) Genotype Database: (A) genetic heterogeneity within blood tissues and (B, C,
and D) within other tissues in an organism. Each of the following databases contains specific information associated with phenotype differences:
(2) DNA editing database, (3) RNA editing database, (4) Coregulators database, (5) Epigenetic database, and (6) Interacting proteins database. (7)
Microenvironment selective pressure for different phenotypes.
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Finally, in the age of data clouds and sophisticated com-
munication platforms, such an institution need not have
a physical structure, but rather could be a virtual insti-
tute, that would then allow experts from all over the
world to participate.
Conclusion
For many years, genetics and related medical research
have been based on the concept that genetic diseases are
the result of alterations to a basically stable human gen-
ome that has limited natural variation within individuals,
so that single or, in the case of multifactorial diseases, a
number of very rare alterations to the human genome
are directly responsible for specific diseases. Our initial
response to the discovery of increased genetic complex-
ity, particularly in multifactorial diseases, has been to
use statistical-based approaches, such as GWAS to try
to identify significant rare variants. However, most of
these studies have yet to produce the breakthroughsinitially predicted, perhaps because they are still analyz-
ing ‘silos of genetic information’ and ignoring the fact
that the genomic makeup and phenotypic modifi-
cations of every individual are both complex and dy-
namic. Indeed, the increasing use of NGS, together
with more accurate expression and pathway analysis
tools, is further broadening our understanding of geno-
type/phenotype relationships, by revealing that the new
genetic landscape is infinitely more complex, not only
between individuals, but also within individuals. In such a
genetic scenario, multifaceted worldwide NGDBs are
likely to be essential tools in our fight to treat genetic-
based disease.
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